11ª edição

New data from the CLEAR study evaluated immunotherapy outcomes on quality of life in patients with advanced kidney cancer

per: Grupo Oncoclínicas
New data from the CLEAR study evaluated immunotherapy outcomes on quality of life in patients with advanced kidney cancer

Scientific commission

André Fay
André Fay
Carlos Augusto Vasconcelos
Carlos Augusto Vasconcelos
Diogo Rosa
Diogo Rosa
Luiz Flávio Coutinho
Luiz Flávio Coutinho

Contributors

Pedro Abreu
Pedro Abreu

According to Pedro Abreu, clinical oncologist at Oncoclínicas Rio de Janeiro, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Motzer et al. reported results of the study’s secondary endpoints comparing the impact of lenvatinib + pembrolizumab or everolimus versus sunitinib on health-related quality of life.

“What was shown was that the combination lenvatinib + pembrolizumab was equal to or superior to sunitinib in both symptom control and quality of life. The combination lenvatinib + everolimus was not superior to sunitinib in terms of quality of life”, he describes.

In his opinion, CLEAR is a study that puts yet another first-line combination treatment option in advanced kidney cancer: “This study specifically focused on quality of life and was able to aggregate more information about the impacts of treatment under that domain. Although it is important to emphasize that although there are more and more studies that analyze the quality of life, we still need to advance further in this field.”x’

Go to our website and read the full article with all the details of this study and others that are part of our coverage of ASCO 2021.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L